| Analysing Time to Event Data in Dementia Prevention Trials: The Example of the GuidAge Study of EGb761 2015 · EGb761® group · Community-dwelling adults aged over 70 years without dementia, with spontaneous memory complaints | 240 mg | 5 years | 1,406 |
| Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba 2005 · Ginkgo group · Postmenopausal women aged 51–67 years | 120 mg | 6 weeks | 45 |
| Efficacy of EGb 761(®) and Betahistine in Treatment of Dizziness/Vertigo: A Randomized Double-Blind Controlled Trial 2026 · EGb 761® group · Adults aged 20 years and older, male and female, with dizziness/vertigo of unclear etiology lasting longer than 1 month | 120 mg | 12 weeks | 43 |
| Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine 2007 · 120 mg GBE · healthy young participants | 120 mg | 1 day | 28 |
| Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma 2003 · Ginkgo biloba extract (GBE) treatment · Patients with bilateral visual field damage resulting from normal tension glaucoma | 120 mg | 4 weeks | 27 |
| Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers 2005 · ginkgo, experiment 1 (acute) · Healthy university students; age range and sex not specified | 120 mg | 1 day | 26 |
| Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity: A Randomised Trial 2016 · Ginkgo Biloba medium dose · Undergraduate volunteers, mean age 20.2 years, female and male, without the listed excluded conditions or regular ginkgo use | 120 mg | 1 day | 24 |
| Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers 2005 · ginkgo, experiment 2 (chronic) · Healthy university students; age range and sex not specified | 120 mg | 6 weeks | 20 |
| A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia 2008 · EGb · Patients with chronic, treatment-resistant schizophrenia maintained on optimal doses of clozapine; age and sex not reported | 120 mg | 12 weeks | 20 |
| Effects on cognition and mood in postmenopausal women of 1-week treatment with Ginkgo biloba 2003 · Ginkgo · Postmenopausal women aged 53–65 years | 120 mg | 7 days | 15 |
| A double-blind, placebo controlled study of Ginkgo biloba extract ('tanakan') in elderly outpatients with mild to moderate memory impairment 1991 · Ginkgo biloba extract group · Patients over age 50 with mild to moderate memory impairment | 120 mg | 24 weeks | 12 |
| The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers 1999 · GBE 120 mg mane · Volunteers aged 30–59 years without a stated condition | 120 mg | 2 days | — |
| A 26-week analysis of a double-blind, placebo-controlled trial of the ginkgo biloba extract EGb 761 in dementia 2000 · EGb 761 group · Patients with mild to severe Alzheimer's disease or multi-infarct dementia | 120 mg | 52 weeks | — |
| Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo 2003 · Group A · Patients with limited, slowly spreading vitiligo | 120 mg | — | — |
| Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults 2006 · Ginkgo group, older adults · Healthy adults aged 55–79 years | 120 mg | 12 weeks | — |
| Ginkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults 2006 · Ginkgo group, young adults · Healthy adults aged 18–43 years | 120 mg | 12 weeks | — |
| A randomized, placebo-controlled trial of Ginkgo biloba L. in treatment of premenstrual syndrome 2009 · experiment group · Students with premenstrual syndrome (PMS) | 120 mg | — | — |
| Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment 1995 · Ginkobene group · Patients aged 51–79 years with age-associated memory impairment | 120 mg | 57 days | — |
| [Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication] 1996 · Ginkgo biloba special extract EGb 761 group · Adults aged 47–82 with Fontaine stage IIb peripheral arterial occlusive disease and intermittent claudication | 120 mg | 24 weeks | — |
| A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group 1997 · EGb · Mildly to severely demented outpatients with Alzheimer disease or multi-infarct dementia | 120 mg | 52 weeks | — |
| Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial 2011 · EGb 761 · Outpatients with mild to moderate Alzheimer’s disease, vascular dementia, or mixed dementia, with neuropsychiatric features; age and sex not reported | 240 mg | 24 weeks | 202 |
| Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg 2012 · EGb 761 group · Patients with mild to moderate dementia (Alzheimer's disease or vascular dementia) associated with neuropsychiatric symptoms | 240 mg | 24 weeks | 200 |
| A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings 2002 · Ginkgo biloba extract EGb 761 · Men and women aged 60 years and older who were cognitively intact, community-dwelling volunteers without a history of dementia or significant neurocognitive impairment | 180 mg | 6 weeks | 131 |
| Efficacy of Getong Tongluo Capsule () for Convalescent-Phase of Ischemic Stroke and Primary Hypertension: A Multicenter, Randomized, Double-Blind, Controlled Trial 2021 · EGB group · Patients with convalescent-phase ischemic stroke and primary hypertension | 80 mg | 12 weeks | 120 |
| Ginkgo biloba extract EGb 761(®) versus pentoxifylline in chronic tinnitus: a randomized, double-blind clinical trial 2018 · EGb 761 group · Men and women aged 30 years or older with subchronic or chronic tinnitus lasting at least 3 months | 240 mg | 12 weeks | 100 |
| Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial 2022 · SID142 group · Adults with peripheral arterial disease; age and sex not specified | 160 mg | 12 weeks | 86 |
| Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial 2011 · EGb-761 · Inpatients with DSM-IV-diagnosed schizophrenia and tardive dyskinesia | 240 mg | 12 weeks | 78 |
| [Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration] 2002 · group I · Patients with impaired vision due to senile, dry macular degeneration; age and sex not specified | 240 mg | 26 weeks | 50 |
| [Ginkgo extract in impaired vision--treatment with special extract EGb 761 of impaired vision due to dry senile macular degeneration] 2002 · group II · Patients with impaired vision due to senile, dry macular degeneration; age and sex not specified | 60 mg | 26 weeks | 49 |
| Investigating the efficacy of Ginkgo biloba on the cognitive function of patients undergoing treatment with electric shock: a double-blind clinical trial 2022 · Intervention group · Adults aged 18–60 with schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder undergoing electroconvulsive therapy | 200 mg | — | 40 |
| Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb. A randomised, double-blind, multicentric clinical trial 1999 · higher dosage · Patients with peripheral arterial occlusive disease, Fontaine stage IIb; age and sex not reported | 240 mg | 24 weeks | 36 |
| [The effect of ginkgo biloba on healthy elderly subjects] 2003 · EGb 761 group · Healthy adults aged 50–65, both sexes, without age-related cognitive impairments | 240 mg | 4 weeks | 34 |
| Effects of Ginkgo biloba extract EGb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment - a randomized double-blind placebo-controlled trial 2016 · EGb 761® group · Adults aged 50–65, male and female, with subjective memory impairment and no dementia | 240 mg | 8 weeks | 31 |
| [Treatment of cognitive and non-cognitive symptoms in cerebrovascular disease] 2014 · EGb 761 · Patients with discirculatory encephalopathy and cognitive impairment; mean age 60.8 years; sex not specified | 240 mg | 24 weeks | 30 |
| [Therapeutic effect of ginkgo biloba extract on postoperative delirium in aged patients] 2018 · Group A (medication group) · Elderly patients with postoperative delirium after tumor surgery | 240 mg | — | 29 |
| Evidence of the regulatory effect of Ginkgo biloba extract on skin blood flow and study of its effects on urinary metabolites in healthy humans 2004 · EGb 761 treatment · healthy middle-aged adults | 240 mg | 3 weeks | 27 |
| Ginkgo biloba special extract LI 1370 improves dual-task walking in patients with MCI: a randomised, double-blind, placebo-controlled exploratory study 2017 · GBE intervention group (IG) · Adults aged 50–85 years with mild cognitive impairment and associated dual-task-related gait impairment | 240 mg | 26 weeks | 25 |
| Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity: A Randomised Trial 2016 · Ginkgo Biloba high dose · Undergraduate volunteers, mean age 20.2 years, female and male, without the listed excluded conditions or regular ginkgo use | 240 mg | 1 day | 24 |
| EGb 761 in control of acute mountain sickness and vascular reactivity to cold exposure 1996 · EGb 761 group · Subjects taking part in a Himalayan expedition, with no stated age or sex; prevention of acute mountain sickness during gradual exposure to moderate altitude | 160 mg | — | 22 |
| Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial 2007 · Ginkgo biloba group · People with multiple sclerosis; age range and sex not reported | 240 mg | 12 weeks | 20 |
| Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent 2002 · ginkgo · Adults residing at sea level before rapid ascent to Mauna Kea, Hawaii (median age 28 years; range 22–53) | 180 mg | 1 day | 12 |
| Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile 2007 · G biloba · Participants residing at sea level with no previous high-altitude experience, ascending to 3696 m | 160 mg | 4 days | 12 |
| The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial 2006 · Ginkgo group · People with multiple sclerosis; age range and sex not specified | 240 mg | 4 weeks | 11 |
| Clinical randomized trial study of hearing aids effectiveness in association with Ginkgo biloba extract (EGb 761) on tinnitus improvement 2020 · Group 1 (G1) · Adults over 18 years, male and female, with tinnitus for at least 3 months and sensorineural or mixed hearing loss | 240 mg | 90 days | 11 |
| Clinical randomized trial study of hearing aids effectiveness in association with Ginkgo biloba extract (EGb 761) on tinnitus improvement 2020 · Group 3 (G3) · Adults over 18 years, male and female, with tinnitus for at least 3 months and sensorineural or mixed hearing loss | 240 mg | 90 days | 11 |
| Effects of Six-Week Ginkgo biloba Supplementation on Aerobic Performance, Blood Pro/Antioxidant Balance, and Serum Brain-Derived Neurotrophic Factor in Physically Active Men 2017 · study group (EGb) · Physically active men aged 20–24 years, healthy and without a stated disease | 80 mg | 6 weeks | 9 |
| The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers 1999 · GBE 150 mg (50 mg t. d.s) · Volunteers aged 30–59 years without a stated condition | 150 mg | 2 days | — |
| The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers 1999 · GBE 240 mg mane · Volunteers aged 30–59 years without a stated condition | 240 mg | 2 days | — |
| An examination of the efficacy of Ginkgo biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults 2000 · Ginkgo biloba extract EGb 761 group · Cognitively intact adults aged 55–86 years | 180 mg | 6 weeks | — |
| Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients 2001 · 120 mg twice daily · Adults with unilateral idiopathic sudden sensorineural hearing loss | 240 mg | 8 weeks | — |
| The efficacy of Ginkgo special extract EGb 761 in patients with tinnitus 2002 · EGb 761 oral treatment · Patients with chronic tinnitus aurium | 160 mg | 12 weeks | — |
| Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial 2003 · EGb 761 group · Patients with mild-to-moderate pre-senile or senile primary degenerative dementia of the Alzheimer type or multi-infarct dementia | 240 mg | 24 weeks | — |
| Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial 2007 · low-dose EGb 761 group · Patients with generalized anxiety disorder or adjustment disorder with anxious mood | 240 mg | 4 weeks | — |
| Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial 2007 · EGb 761-treated patients · Patients with dementia and neuropsychiatric features, including probable or possible Alzheimer's disease or vascular dementia | 240 mg | 22 weeks | — |
| [Therapeutic follow-up using automatic perimetry in chronic cerebroretinal ischemia in elderly patients. Prospective double-blind study with graduated dose ginkgo biloba treatment (EGb 761)] 1991 · Group B · Elderly patients with chronic cerebroretinal ischemia; mean age 74.9 years | 160 mg | 4 weeks | — |
| [Therapeutic follow-up using automatic perimetry in chronic cerebroretinal ischemia in elderly patients. Prospective double-blind study with graduated dose ginkgo biloba treatment (EGb 761)] 1991 · Group A · Elderly patients with chronic cerebroretinal ischemia; mean age 74.9 years | 80 mg | 4 weeks | — |
| Efficacy and tolerability of Ginkgo biloba extract EGb 761 by type of dementia: analyses of a randomised controlled trial 2009 · EGb 761 · Patients aged 50 years or above with dementia and neuropsychiatric features; subgroups had Alzheimer's disease or probable vascular dementia | 240 mg | 22 weeks | — |
| Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial 2010 · EGb 761® group · Outpatients with mild to moderate Alzheimer’s disease, vascular dementia, or Alzheimer’s disease with cerebrovascular disease, all with neuropsychiatric features; age and sex not reported | 240 mg | 24 weeks | — |
| Specific memory effects of Ginkgo biloba extract EGb 761 in middle-aged healthy volunteers 2011 · EGb 761 · Healthy adults aged 45–56 years | 240 mg | 6 weeks | — |
| Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial 2012 · EGb 761® treatment · Outpatients aged 50 years or older with mild to moderate dementia, including Alzheimer's disease or vascular dementia, and neuropsychiatric features | 240 mg | 24 weeks | — |
| [Cerebral insufficiency--treatment with Ginkgo-biloba extract. Time of onset of effect in a double-blind study with 60 inpatients] 1990 · Ginkgo-biloba group · Inpatients with cerebral insufficiency and leading symptom of depressive mood | 160 mg | 6 weeks | — |
| Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba 2012 · EGb-761 treatment · Chinese patients with schizophrenia and tardive dyskinesia | 240 mg | 12 weeks | — |
| Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial 2014 · EGb 761-treated group · Patients with mild cognitive impairment and a score of at least 6 on the 12-item Neuropsychiatric Inventory | 240 mg | 24 weeks | — |
| Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A randomized, placebo-controlled, trial 2015 · Ginkgo biloba group · Children and adolescents with ADHD receiving methylphenidate | 80 mg | 6 weeks | — |
| The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis scardica (Greek Mountain Tea) Extract: A Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans 2018 · 240 mg Ginkgo biloba extract · Healthy older adults; mean age 60.3 years; men and women | 240 mg | 4 weeks | — |
| Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial 2024 · EGb761 group · Han Chinese adults aged 25–75 with schizophrenia and tardive dyskinesia, on stable antipsychotic medication | 240 mg | 12 weeks | — |
| Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia 1996 · EGb 761 · Presenile and senile outpatients with mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia | 240 mg | 24 weeks | — |
| Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type 1997 · EGb 761 group · Outpatients with mild to moderate dementia of the Alzheimer type; age and sex not reported | 240 mg | 90 days | — |
| The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial 2018 · GKB group · Adults aged 25–65, both sexes, with type 2 diabetes inadequately controlled by metformin | 120 mg | 90 days | 30 |
| Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers 2002 · EGb 761 · Healthy young volunteers; men and women; no stated condition | 120 mg | 1 day | — |
| [Treatment of Early Diabetic Retinopathy by Liuwei Dihuang Pill Combined Ginkao Leaf Tablet] 2016 · treatment group · Adults with type 2 diabetes mellitus and early diabetic retinopathy | 57.6 mg | 2 years | 70 |
| Ginkgo biloba extract improved cognitive and neurological functions of acute ischaemic stroke: a randomised controlled trial 2017 · GBE group · Adults aged 18–80 with acute ischaemic stroke | 450 mg | 180 days | 179 |
| [Effects of Ginkgo biloba extract in improving episodic memory of patients with mild cognitive impairment: a randomized controlled trial] 2012 · Ginkgo biloba leaf tablet group (treatment group) · Generally healthy, ambulatory or ambulatory-aided adults aged 60–85 with amnestic mild cognitive impairment and a memory complaint | 57.6 mg | 26 weeks | 60 |
| [Ginkgo leaves tablet improved the memory quotient of patients with mild cognitive impairment: a clinical observation] 2014 · treatment group · Patients with mild cognitive impairment; age and sex not reported | 57.6 mg | 1 year | 58 |
| A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia 2001 · EGb plus haloperidol · Adults with chronic, treatment-resistant schizophrenia; age and sex not stated | 360 mg | 12 weeks | 56 |
| Effects of Ginkgo biloba on mental functioning in healthy volunteers 2003 · EGb 761-treatment group · Healthy volunteers aged 50–65 years without age-associated cognitive impairment | 720 mg | 4 weeks | 34 |
| Effect of Pushen capsule for treating vascular mild cognitive impairment: a pilot observational study 2019 · control group (Ginkgo biloba tablets) · Adults aged 18 years or older with vascular mild cognitive impairment following stroke or lacunar infarction | 57.6 mg | 12 weeks | 32 |
| Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults 2002 · Ginkgo biloba · Healthy young adult volunteers; age range and sex not stated | 360 mg | 1 day | 20 |
| Effect of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects 1993 · 320 mg Ginkgo biloba extract (EGb 761) · Elderly men and women, mean age 69.3 years, with slight age-related memory impairment | 320 mg | 1 day | 18 |
| Effect of two doses of ginkgo biloba extract (EGb 761) on the dual-coding test in elderly subjects 1993 · 600 mg Ginkgo biloba extract (EGb 761) · Elderly men and women, mean age 69.3 years, with slight age-related memory impairment | 600 mg | 1 day | 18 |
| The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers 1999 · GBE 300 mg (100 mg t.d.s.) · Volunteers aged 30–59 years without a stated condition | 300 mg | 2 days | — |
| Effect of treatment with Ginkgo biloba extract EGb 761 (oral) on unilateral idiopathic sudden hearing loss in a prospective randomized double-blind study of 106 outpatients 2001 · 12 mg twice daily · Adults with unilateral idiopathic sudden sensorineural hearing loss | 24 mg | 8 weeks | — |
| Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial 2007 · high-dose EGb 761 group · Patients with generalized anxiety disorder or adjustment disorder with anxious mood | 480 mg | 4 weeks | — |
| Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia 2012 · combined treatment group · Patients with vascular cognitive impairment of no dementia (VCIND); age and sex not reported | 57.6 mg | 90 days | — |
| Comparison of integrated traditional Chinese and western medicine therapy on vascular cognitive impairment with no dementia 2015 · combined treatment group · People with vascular cognitive impairment with no dementia (age and sex not reported) | 57.6 mg | 90 days | — |
| Study of the antiischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPo2 determination 1994 · EGb 761 group · Patients aged 44–73 with stage II claudicating atherosclerotic arterial occlusive disease | 320 mg | 4 weeks | — |
| [Therapeutic effect of shuxuening combining neuroleptics for the treatment of chronic schizophrenia--a double blind study] 1997 · SXN group · People with chronic schizophrenia; age and sex not reported | 360 mg | 16 weeks | — |
| A double-blind, randomized clinical trial of dietary supplementation on cognitive and immune functioning in healthy older adults 2014 · Ginkgo Synergy® plus Choline · Adults aged 60 years and older without cognitive impairment or specified major illnesses | 200 mg | 26 weeks | 33 |
| Effect of Memo®, a natural formula combination, on Mini-Mental State Examination scores in patients with mild cognitive impairment 2013 · Memo group · Men and women aged 50–80 years with mild cognitive impairment | 120 mg | 4 weeks | 30 |
| Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine 2007 · 120 mg GBE complexed with phosphatidylserine (Virtiva) · healthy young participants | 120 mg | 1 day | 28 |
| Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine 2007 · 120 mg GBE complexed with phosphatidylcholine · healthy young participants | 120 mg | 1 day | 28 |
| The effect of Sailuotong (SLT) on neurocognitive and cardiovascular function in healthy adults: a randomised, double-blind, placebo controlled crossover pilot trial 2016 · SLT · Healthy adults; 16 participants completed the crossover trial | 54.5 mg | 7 days | 16 |
| The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers 2000 · 160 mg b.i.d. dosing regimen · Healthy middle-aged volunteers | 120 mg | 14 weeks | — |
| The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers 2000 · 320 mg o.d. dosing regimen · Healthy middle-aged volunteers | 60 mg | 14 weeks | — |
| Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand 2002 · Ginkgo-Ginseng combination, 320 mg · Healthy young adults, mean age 21 years | 320 mg | 1 day | — |
| Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand 2002 · Ginkgo-Ginseng combination, 640 mg · Healthy young adults, mean age 21 years | 640 mg | 1 day | — |
| Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand 2002 · Ginkgo-Ginseng combination, 960 mg · Healthy young adults, mean age 21 years | 960 mg | 1 day | — |
| A randomized, double-blind, placebo-controlled study of Cistanche tubulosa and Ginkgo biloba extracts for the improvement of cognitive function in middle-aged and elderly people 2024 · CG group · Chinese middle-aged and elderly people at risk of neurodegenerative diseases | 27 mg | 90 days | — |
| A double-blind, randomised cross-over study to evaluate the absorption of a commercially available Ginkgo biloba extract compared to the liposomal extract Ginkgosome 2022 · Ginkgosome™ group · Healthy males and females aged 18–40 years with a healthy BMI and no clinically significant medical conditions | 120 mg | 1 day | 14 |
| A double-blind, randomised cross-over study to evaluate the absorption of a commercially available Ginkgo biloba extract compared to the liposomal extract Ginkgosome 2022 · Standard group · Healthy males and females aged 18–40 years with a healthy BMI and no clinically significant medical conditions | 120 mg | 1 day | 14 |
| Investigating the Effects of a Multinutrient Supplement on Cognition, Mood and Biochemical Markers in Middle-Aged Adults with 'Optimal' and 'Sub-Optimal' Diets: A Randomized Double Blind Placebo Controlled Trial 2022 · active supplementation · Adults aged 40–65 years, healthy and without neurological, cognitive, mood or psychiatric disorders; participants had either an optimal or sub-optimal diet | 6 g | 12 weeks | 70 |
| The ingestion of Ginkgo biloba extract (EGb 761) inhibits arachidonic acid-mediated platelet aggregation and thromboxane B2 production in healthy volunteers 2004 · EGb 761 · Non-diabetic volunteers, mean age 39 ± 13 years; sex not reported | 120 mg | 90 days | 12 |
| Ginkgo biloba extract increases ocular blood flow velocity 1999 · Ginkgo biloba extract treatment · Healthy volunteers, 34 ± 3 years; 8 women and 3 men | 120 mg | 2 days | 11 |
| The effect of Ginkgo biloba extract on genotoxic damage in patients with differentiated thyroid carcinoma receiving thyroid remnant ablation with iodine-131 2012 · GBE · Patients aged 18–73 with differentiated thyroid carcinoma receiving iodine-131 thyroid remnant ablation | 120 mg | 30 days | 10 |
| Ticlopidine with Ginkgo Biloba extract: a feasible combination for patients with acute cerebral ischemia 2013 · ticlopidine plus Gingko Biloba extract (EGb) · Patients with acute cerebral ischemia | 160 mg | 90 days | 43 |
| Clinical and genomic safety of treatment with Ginkgo biloba L. leaf extract (IDN 5933/Ginkgoselect®Plus) in elderly: a randomised placebo-controlled clinical trial [GiBiEx] 2018 · IDN 5933 · Elderly nursing-home residents aged 65 years or older, with chronic conditions; men and women | 240 mg | 26 weeks | 34 |
| A new ginkgo fresh plant extract increases microcirculation and radical scavenging activity in elderly patients 2011 · ginkgo extract group · Elderly patients; sex and specific condition not stated | 180 mg | 30 days | 16 |
| Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma 2011 · GBE-treated study group · Adults aged 18–80 with normal tension glaucoma | 160 mg | 4 weeks | 15 |
| Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects 2013 · Simvastatin co-treated with GBE · Healthy volunteers; age range and sex not reported | 240 mg | 2 weeks | 14 |
| Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba 2005 · Ginkgo biloba supplementation · Healthy elderly adults, 67 ± 5.2 years; 6 men and 6 women | 240 mg | 4 weeks | 12 |
| Pharmacokinetics and bioavailability of a Ginkgo biloba extract 2002 · 40 mg twice daily · 12 healthy volunteers; sex and age not reported | 80 mg | 7 days | — |
| Pharmacokinetics and bioavailability of a Ginkgo biloba extract 2002 · 80 mg once daily · 12 healthy volunteers; sex and age not reported | 80 mg | 7 days | — |
| [Effect of extract of ginkgo bilboa leaf on early diabetic nephropathy] 2005 · treated group · Patients with early diabetic nephropathy | 28.8 mg | 90 days | 34 |
| Ginkgo biloba extract (EGb 761) pretreatment limits free radical-induced oxidative stress in patients undergoing coronary bypass surgery 1997 · EGb 761 · Patients undergoing aortic valve replacement and coronary bypass surgery | 320 mg | 5 days | 8 |
| The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial 2006 · EGb plus haloperidol · Adults with schizophrenia who were inpatients | 360 mg | 12 weeks | — |
| [Effect of combined therapy with hypha Cordyceps and ginkgo leaf tablet on micro-inflammation in patients undergoing maintenance hemodialysis] 2008 · treated group · Patients undergoing long-term maintenance hemodialysis; age and sex not reported | 690 mg | 90 days | 33 |